Here are the 10-K annual reports from Candel Therapeutics, Inc. (CADL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CADL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CADL filings page.
Candel Therapeutics, Inc. reports its annual update as a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies for solid tumors. Its lead adenoviral candidate, aglatimagene besadenovec, showed a statistically significant disease-free survival benefit in a 745‑patient phase 3 trial in intermediate‑ and high‑risk localized prostate cancer (hazard ratio 0.70; p=0.0155), received RMAT and Fast Track designations, and is being prepared for a planned Biologics License Application submission in the fourth quarter of 2026.
The company is also advancing aglatimagene in non-small cell lung cancer, where a phase 2a trial in patients progressing on checkpoint inhibitors reported median overall survival up to 25.4 months in non-squamous disease versus 9.8–11.8 months in published chemotherapy data. A pancreatic cancer study showed prolonged survival but further work is paused pending external funding. Candel’s HSV-based candidate, linoserpaturev, has produced encouraging survival and immune-activation signals in recurrent high‑grade glioma, supported by Fast Track and Orphan Drug designations, with multiple-dose data and enabling work for a future randomized phase 2 underway. The company also highlights its enLIGHTEN™ Discovery Platform for next‑generation viral immunotherapies, while noting it has no product revenue, expects continuing losses, relies on external manufacturing, and must raise substantial additional capital.